910037-12-6 Purity
96%
If you have any other questions or need other size, please get a quote.
Specification
4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydropyrido[3,2-b][1,4]oxazine
C14H21BN2O3
276.14 g/mol
0
5
276.1645227 g/mol
43.8 2
20
Yes
PDTRXHRSCGNYFD-UHFFFAOYSA-N
Reference: [1]Current Patent Assignee: SPERO THERAPEUTICS INC - WO2009/74812, 2009, A1
Location in patent: Page/Page column 32
Reference: [1]Current Patent Assignee: GENERAL ELECTRIC CO - EP2634177, 2013, A1
Location in patent: Paragraph 0440; 0441
* For details of the synthesis route, please refer to the original source to ensure accuracy.